-
My Account
In App
My Account
| BUY | SELL | ||
|---|---|---|---|
| QTY | PRICE | PRICE | QTY |
| 25 | 186.40 | 186.85 | 322 |
| 572 | 186.30 | 186.95 | 322 |
| 25 | 186.25 | 187.10 | 1 |
| 172 | 186.20 | 187.20 | 1 |
| 24 | 186.05 | 190.00 | 220 |
| 0 | Total | Total | 0 |
| BUY | SELL | ||
|---|---|---|---|
| QTY | PRICE | PRICE | QTY |
| 25 | 186.40 | 186.85 | 322 |
| 572 | 186.30 | 186.95 | 322 |
| 25 | 186.25 | 187.10 | 1 |
| 172 | 186.20 | 187.20 | 1 |
| 24 | 186.05 | 190.00 | 220 |
| 0 | Total | Total | 0 |
As on --
(OI , PRICE )
As on --
| Open | 188.38 |
| Previous Close | 188.38 |
| Volume | 3,111,398.00 |
| Value (Lacs) | 5,797.47 |
| VWAP | 0.00 |
| Beta | |
| Mkt Cap (Rs. Cr.) | 24,768 |
| High | 189.91 |
| Low | 185.25 |
| UC Limit | 0.00 |
| LC Limit | 0.00 |
| 52 Week High | 283.90 |
| 52 Week Low | 181.73 |
| Face Value | 10.00 |
| All Time High | 307.90 |
| All Time Low | 0.00 |
| 20D Avg Volume | 4,236,915 |
| 20D Avg Delivery(%) | 24.91 |
| Book Value Per Share | 59.53 |
| Dividend Yield | 0.08 |
| TTM EPS See historical trend | -0.18 |
| TTM PE See historical trend | -- (Low PE) |
| P/B See historical trend | 3.13 (Average P/B) |
| Sector PE | 39.58 |
*Delayed by 20 seconds.
Stock Score
Get detailed analysis with Moneycontrol Stock Insights.
| Moving Averages | -- |
| Technical Indicators | -- |
| Moving Averages Crossovers | -- |
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.
| R1 | - - | Pivot - - |
S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.
| Days | |
|---|---|
| 5 | - - |
| 10 | - - |
| 20 | - - |
| 50 | - - |
| 100 | - - |
| 200 | - - |
| Moving Averages | -- |
| Technical Indicators | -- |
| Moving Averages Crossovers | -- |
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the week, calculated based on price range of the previous trading week.
| R1 | - - | Pivot - - |
S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the week, calculated based on price range of the previous trading week.
| Days |
|---|
| Moving Averages | -- |
| Technical Indicators | -- |
| Moving Averages Crossovers | -- |
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.
| R1 | - - | Pivot - - |
S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.
| Days |
|---|
| 1 Week | --% | |
| 1 Month | --% | |
| 3 Months | --% | |
| YTD | --% | |
| 1 Year | --% | |
| 3 Years | --% |
2 out of 3 years Piramal Pharma has given positive returns in November.
| Month | Max. Positive Change(%) | Avg. Positive Change(%) | Max. Negative Change(%) | Avg. Negative Change(%) | Average Change(%) |
|---|---|---|---|---|---|
| November | 21.15% (2023) | 10.63% | -6.66% (2025) | -6.66% | 4.86% |
Piramal Pharma Standalone September 2025 Net Sales at Rs 1,127.26 crore, down 12.23% Y-o-Y Nov 12 2025 10:01 AM
Piramal Pharma Consolidated September 2025 Net Sales at Rs 2,043.72 crore, down 8.83% Y-o-Y Nov 06 2025 11:13 AM
Piramal Pharma posts Rs 99 crore loss in Q2FY26 weighed down by CDMO business Nov 05 2025 10:44 PM
Indian CRDMOs eye growth as US Biosecure Act and US-China trade tensions may redraw supply chains Oct 22 2025 11:07 AM
Further down as new listing of pharma coming in market. Then this will show strength. View more | 1
Posted by : Nepha9
Posted by : The Fixed Income
Repost this message
Your Portfolio Deserves a Core of Stability, Start with Rajasthan Government Security 8.84% RAJASTHAN SDL 2028 ✔️ Coupon: 8.23% ✔️ Tenor: 1y 2m (Maturity: 12/Feb/2027) High Return Government Securities | Listed Add stability to your portfolio with a Government Security that matures quickly yet delivers predictable performance. ???? Explore on The Fixed Income: https://www.thefixedincome.com/product/dXhTcllnPT0=/884-rajasthan-sdl-2028?utm_source=Moneycontrol&utm_medium=Forum&utm_campaign=Product_list
*Transaction of a minimum quantity of 500,000 shares or a minimum value of Rs 5 crore.
| Qty 6856958 | Price 219.7 | % Traded 0.52 |
| Qty 6856958 | Price 219.88 | % Traded 0.52 |
*A bulk deal is a trade where total quantity of shares bought or sold is more than 0.5% of the equity shares of a company listed on the exchange.
| Date | Agenda |
|---|
| Ex-Date | Type | Dividend (Rs) |
|---|
| Announcement Date | Ex-Bonus | Ratio |
|---|
| Ex-Split | Old FV | New FV |
|---|
| Ex-Right | Ratio | Premium |
|---|
| Date | Agenda |
|---|
| Company Name | Price | % Chg | MCap(Cr) | TTM PE | P/B | ROE(%) | 1 Yr Perform(%) | Net Profit(Rs.) | Net Sales(Rs.) | Debt to Equity |
|---|---|---|---|---|---|---|---|---|---|---|
| Piramal Pharma | 186.33 | -1.09 | 24,767.88 | - | 3.13 | 1.12 | -25.51 | 18 | 9,151 | 0.58 |
| Sun Pharma | 1,780.80 | 0.06 | 427,273.57 | 40.89 | 5.92 | 15.13 | -0.81 | 10,980 | 52,578 | 0.03 |
| Divis Labs | 6,359.00 | -0.22 | 168,811.47 | 67.93 | 11.28 | 14.63 | 6.01 | 2,191 | 9,360 | 0.00 |
| Torrent Pharma | 3,718.40 | 0.87 | 125,847.55 | 58.81 | 16.77 | 25.17 | 17.41 | 1,911 | 11,516 | 0.40 |
| Cipla | 1,504.00 | -0.52 | 121,488.79 | 22.33 | 3.89 | 16.90 | 1.18 | 5,291 | 27,547 | 0.00 |
Sharpest Opinions & Actionable Insights 
Exclusive Webinars 
Research & Expert Technical Analysis 
